Pfizer to buy Excaliard Pharma for skin drug
(Reuters) - Pfizer Inc (PFE.N) agreed to buy privately held biopharmaceutical company Excaliard Pharmaceuticals for an undisclosed sum, to gain access to Excaliard's experimental skin scarring drug.
Pfizer, which expects to close the deal by the year end, said Excaliard will receive an upfront payment and related milestone payments.
The drug EXC 001, which is in mid-stage trials, was co-developed by Excaliard and Isis Pharmaceuticals Inc (ISIS.O) to treat skin fibrosis, characterized by the formation of excess fibrous connective tissue.
Separately, Isis said it will receive up to $14 million from Pfizer for its stake in Excaliard.
"The science behind Excaliard's lead compound aligns well with our R&D focus on new treatments for fibrosis and tissue remodeling," Pfizer said.
Pfizer shares closed at $18.96 on Monday on the New York Stock Exchange, while Isis shares closed at $6.57 on Nasdaq.
(Reporting by Balaji Sridharan in Bangalore; Editing by Esha Dey)
DETROIT - General Motors Co said on Tuesday Chief Executive Officer Dan Akerson will step down next month and be replaced by global product development chief Mary Barra, who will become the first woman to lead a global automaker. | Video
WASHINGTON - U.S. small business sentiment bounced back from a seven-month low in November, with owners setting their sights on creating more jobs and expanding operations.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.